Neuromuscular Disorders
Volume 20, Issue 2 , Pages 98-101 , February 2010

Ca2+ sensitizers: An emerging class of agents for counterbalancing weakness in skeletal muscle diseases?

  • Julien Ochala

      Affiliations

    • Corresponding Author InformationAddress: Department of Neuroscience, Clinical Neurophysiology, University Hospital, Entrance 85, 3rd Floor, SE-751 85 Uppsala, Sweden. Tel.: +46 18 611 9338; fax: +46 18 55 6106.

Received 5 September 2009 ,Revised 14 November 2009 ,Accepted 17 November 2009.

References 

  1. Melzer W, Herrmann-Frank A, Luttgau HC. The role of Ca2+ ions in excitation–contraction coupling of skeletal muscle fibres. Biochim Biophys Acta. 1995;1241:59–116
  2. Gordon AM, Homsher E, Regnier M. Regulation of contraction in striated muscle. Physiol Rev. 2000;80:853–924
  3. Shiner JS, Solaro RJ. The hill coefficient for the Ca2+-activation of striated muscle contraction. Biophys J. 1984;46:541–543
  4. Levine S, Nguyen T, Taylor N, et al. Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans. N Engl J Med. 2008;358:1327–1335
  5. Ottenheijm CA, Heunks LM, Sieck GC, et al. Diaphragm dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172:200–205
  6. Levine S, Nguyen T, Kaiser LR, et al. Human diaphragm remodeling associated with chronic obstructive pulmonary disease: clinical implications. Am J Respir Crit Care Med. 2003;168:706–713
  7. Larsson L, Li X, Edstrom L, et al. Acute quadriplegia and loss of muscle myosin in patients treated with nondepolarizing neuromuscular blocking agents and corticosteroids: mechanisms at the cellular and molecular levels. Crit Care Med. 2000;28:34–45
  8. Ochala J, Larsson L. Effects of a preferential myosin loss on Ca2+ activation of force generation in single human skeletal muscle fibres. Exp Physiol. 2008;93:486–495
  9. Ochala J, Li M, Ohlsson M, et al. Defective regulation of contractile function in muscle fibres carrying an E41K beta-tropomyosin mutation. J Physiol. 2008;586:2993–3004
  10. Riley DA, Bain JL, Romatowski JG, et al. Skeletal muscle fiber atrophy: altered thin filament density changes slow fiber force and shortening velocity. Am J Physiol Cell Physiol. 2005;288:360–365
  11. Mounier Y, Tiffreau V, Montel V, et al. Phenotypical transitions and Ca2+ activation properties in human muscle fibers: effects of a 60-day bed rest and countermeasures. J Appl Physiol. 2009;106:1086–1099
  12. Toursel T, Bastide B, Stevens L, et al. Alterations in contractile properties and expression of myofibrillar proteins in wobbler mouse muscles. Exp Neurol. 2000;162:311–320
  13. Stevens L, Bastide B, Maurage CA, et al. Childhood spinal muscular atrophy induces alterations in contractile and regulatory protein isoform expressions. Neuropathol Appl Neurobiol. 2008;34:659–670
  14. Barclay CJ, Woledge RC, Curtin NA. Energy turnover for Ca2+ cycling in skeletal muscle. J Muscle Res Cell Motil. 2007;28:259–274
  15. Adhikari BB, Regnier M, Rivera AJ, et al. Cardiac length dependence of force and force redevelopment kinetics with altered cross-bridge cycling. Biophys J. 2004;87:1784–1794
  16. Brenner B. Effect of Ca2+ on cross-bridge turnover kinetics in skinned single rabbit psoas fibers: implications for regulation of muscle contraction. Proc Natl Acad Sci USA. 1988;85:3265–3269
  17. Endoh M. Cardiac Ca2+ signaling and Ca2+ sensitizers. Circ J. 2008;72:1915–1925
  18. Kass DA, Solaro RJ. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation. 2006;113:305–315
  19. Suga H. Ventricular energetics. Physiol Rev. 1990;70:247–277
  20. Sorsa T, Heikkinen S, Abbott MB, et al. Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. J Biol Chem. 2001;276:9337–9343
  21. Pollesello P, Ovaska M, Kaivola J, et al. Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. J Biol Chem. 1994;269:28584–28590
  22. Pan BS, Johnson RG. Interaction of cardiotonic thiadiazinone derivatives with cardiac troponin C. J Biol Chem. 1996;271:817–823
  23. Wang X, Li MX, Spyracopoulos L, et al. Structure of the C-domain of human cardiac troponin C in complex with the Ca2+ sensitizing drug EMD 57033. J Biol Chem. 2001;276:25456–25466
  24. van Hees HW, Dekhuijzen PN, Heunks LM. Levosimendan enhances force generation of diaphragm muscle from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;179:41–47
  25. O’Connell B, Stephenson DG, Blazev R, et al. Troponin C isoform composition determines differences in Sr2+-activation characteristics between rat diaphragm fibers. Am J Physiol Cell Physiol. 2004;287:79–87
  26. Baudenbacher F, Schober T, Pinto JR, et al. Myofilament Ca2+ sensitization causes susceptibility to cardiac arrhythmia in mice. J Clin Invest. 2008;118:3893–3903
  27. Endoh M. Mechanisms of action of novel cardiotonic agents. J Cardiovasc Pharmacol. 2002;40:323–338
  28. Antoniades C, Antonopoulos AS, Tousoulis D, et al. Relationship between the pharmacokinetics of levosimendan and its effects on cardiovascular system. Curr Drug Metab. 2009;10:95–103
  29. Ochala J, Radell PJ, Eriksson LI, et al. EMD 57033 partially reverses ventilator-induced diaphragm muscle fibre calcium desensitisation. Pflugers Arch, in press.

PII: S0960-8966(09)00692-0

doi: 10.1016/j.nmd.2009.11.010

Neuromuscular Disorders
Volume 20, Issue 2 , Pages 98-101 , February 2010

Article Tools

* Image Usage & Resolution